DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
DBV Technologies S.A.NASDAQ: DBVT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $13.4M rose 211.0% year over year, ahead of the +65.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.1% from the prior quarter. Over 3 fiscal years it compounded at +17.2% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $8.72M (-69.2%) for the fiscal year ending Dec 2026, a slowdown from the +18.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $13.4M+18.1% QoQ
- Last fiscal yearDec 2025
- $28.28M+18.8% YoY
- LTMMar 2026
- $38.19M+65.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 28.28M USD
- Year-over-year change
- +18.8%
- 4-year CAGR
- +4.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.28M | +18.8% |
| FY2024 | 2024-12-31 | 23.81M | -25.4% |
| FY2023 | 2023-12-31 | 31.94M | +81.8% |
| FY2022 | 2022-12-31 | 17.56M | -26.3% |
| FY2021 | 2021-12-31 | 23.83M | — |
Selling, General & Admin vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 selling, general & admin of $38.19M is the 2nd highest of the 11 companies compared; the peer median is $30.32M.
- Its year-over-year change of +65.9% is the highest of 10, against a peer median of -0.8%.
- Over three fiscal years its annual growth of +17.2% compares with a peer median of +18.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $99.54M | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $38.19M | +65.9% | +17.2% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $35.46M | -13.0% | +55.9% | — |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $35.41M | +41.6% | +106.4% | — |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $30.49M | -15.8% | +18.8% | 793.5% | |
| LTM Mar 2026 | $30.16M | +39.3% | +17.9% | 83769.4% | |
| LTM Mar 2026 | $21.89M | -3.6% | +59.0% | — | |
| LTM Mar 2026 | $19.82M | +7.4% | +14.2% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
| LTM Mar 2026 | $9.18M | +20.3% | -1.1% | 13.5% | |
| Peer median (excluding DBVT) | $30.32M | -0.8% | +18.4% | 419.9% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.71M | 4.8M | 15.73M | 0 | 0 |
| Cost of Revenue | 9.27M | 20.3M | 0 | 6.81M | 17.67M |
| Gross Profit | (3.57M) | (15.5M) | 15.73M | (6.81M) | (17.67M) |
| Gross Margin | -62.5% | -322.9% | 100.0% | — | — |
| Research & Development | 70.34M | 75.5M | 60.22M | 89.9M | 116.68M |
| Selling, General & Admin | 23.83M | 17.56M | 31.94M | 23.81M | 28.28M |
| Operating Expenses | 93.93M | 101.48M | 92.16M | 113.71M | 147.06M |
| Depreciation & Amortization | 8.38M | 20.3M | 13.16M | 6.81M | 7.73M |
| EBITDA | (91.16M) | (76.68M) | (63.27M) | (110.99M) | (139.32M) |
| EBITDA Margin | -1597.0% | -1597.5% | -402.3% | — | — |
| Operating Income | (98.61M) | (96.63M) | (76.43M) | (120.53M) | (147.06M) |
| Operating Margin | -1727.6% | -2013.1% | -486.0% | — | — |
| Interest Income | 521K | 406.29K | 3.71M | 2.73M | 601.86K |
| Interest Expense | 690K | 427K | 0 | 0 | 0 |
| Other Income / Expenses | 424K | 427K | 3.71M | 2.73M | 600K |
| Income Before Tax | (98.19M) | (96.2M) | (72.72M) | (117.8M) | (146.46M) |
| Pre-Tax Margin | -1720.2% | -2004.3% | -462.4% | — | — |
| Income Tax Expense | (381K) | 70K | 7K | (4.08M) | 491K |
| Net Income | (97.81M) | (96.3M) | (72.73M) | (113.72M) | (146.95M) |
| Net Margin | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (Basic) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| EPS (Diluted) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| Weighted Avg Shares | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
| Weighted Avg Shares (Diluted) | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.